93 related articles for article (PubMed ID: 9345375)
1. Immunomodulation with linomide: possible novel therapy for multiple sclerosis.
Abramsky O; Lehmann D; Karussis D
Mult Scler; 1996 Nov; 2(4):206-10. PubMed ID: 9345375
[TBL] [Abstract][Full Text] [Related]
2. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation.
Karussis DM; Meiner Z; Lehmann D; Gomori JM; Schwarz A; Linde A; Abramsky O
Neurology; 1996 Aug; 47(2):341-6. PubMed ID: 8757002
[TBL] [Abstract][Full Text] [Related]
3. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Neurology; 1996 Oct; 47(4):895-900. PubMed ID: 8857715
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Kalland T; Abramsky O
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6400-4. PubMed ID: 8341645
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells.
Lehmann D; Karussis D; Mizrachi-Koll R; Linde AS; Abramsky O
Clin Immunol Immunopathol; 1997 Nov; 85(2):202-9. PubMed ID: 9344704
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis.
Lehmann D; Karussis DM; Fluresco D; Mizrachi-Koll R; Ovadia H; Shezen E; Kalland T; Abramsky O
J Neuroimmunol; 1997 Apr; 74(1-2):102-10. PubMed ID: 9119961
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide.
Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Ben-Nun A; Kalland T; Abramsky O
Ann Neurol; 1993 Nov; 34(5):654-60. PubMed ID: 8239559
[TBL] [Abstract][Full Text] [Related]
8. Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats.
Zhu J; Diab A; Mustafa M; Levi M; Wahren B; Björk J; Hedlund G
J Neurol Sci; 1998 Oct; 160(2):113-20. PubMed ID: 9849793
[TBL] [Abstract][Full Text] [Related]
9. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials.
Tan IL; Lycklama à Nijeholt GJ; Polman CH; Adèr HJ; Barkhof F
Mult Scler; 2000 Apr; 6(2):99-104. PubMed ID: 10773855
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages.
Dahlén E; Andersson M; Dawe K; Tellander AC; Brunmark C; Björk A; Hedlund G
Autoimmunity; 2000 Oct; 32(3):199-211. PubMed ID: 11092700
[TBL] [Abstract][Full Text] [Related]
11. Failure of treatment with Linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis.
Drescher KM; Rivera-Quinones C; Lucchinetti CF; Rodriguez M
J Neuroimmunol; 1998 Aug; 88(1-2):111-9. PubMed ID: 9688332
[TBL] [Abstract][Full Text] [Related]
12. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.
Wolinsky JS; Narayana PA; Noseworthy JH; Lublin FD; Whitaker JN; Linde A; Gjörstrup P; Sullivan HC
Neurology; 2000 May; 54(9):1734-41. PubMed ID: 10802777
[TBL] [Abstract][Full Text] [Related]
13. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Mult Scler; 1996 Jul; 1(6):348. PubMed ID: 9345415
[No Abstract] [Full Text] [Related]
14. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines.
Diab A; Michael L; Wahren B; Deng GM; Björk J; Hedlund G; Zhu J
J Neuroimmunol; 1998 May; 85(2):146-54. PubMed ID: 9630163
[TBL] [Abstract][Full Text] [Related]
15. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators.
Noseworthy JH; Wolinsky JS; Lublin FD; Whitaker JN; Linde A; Gjorstrup P; Sullivan HC
Neurology; 2000 May; 54(9):1726-33. PubMed ID: 10802775
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids.
Pekarski O; Björk J; Hedlund G; Andersson G
Autoimmunity; 1998; 28(4):235-41. PubMed ID: 9892505
[TBL] [Abstract][Full Text] [Related]
17. Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system.
Hedlund G; Link H; Zhu J; Xiao BG
Int Immunopharmacol; 2001 Jun; 1(6):1123-30. PubMed ID: 11407306
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia.
Bengtsson M; Simonsson B; Carlsson K; Nilsson B; Smedmyr B; Termander B; Oberg G; Tötterman TH
Transplantation; 1992 Apr; 53(4):882-8. PubMed ID: 1566354
[TBL] [Abstract][Full Text] [Related]
19. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial.
Coutant R; Landais P; Rosilio M; Johnsen C; Lahlou N; Chatelain P; Carel JC; Ludvigsson J; Boitard C; Bougnères PF
Diabetologia; 1998 Sep; 41(9):1040-6. PubMed ID: 9754822
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation of autoimmunity by linomide.
Karussis DM; Lehmann D; Slavin S; Kalland T; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Abramsky O
Isr J Med Sci; 1995 Jan; 31(1):38-41. PubMed ID: 7836046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
